
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ASKB589
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Aosaikang Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ASKB589 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Gastroesophageal Junction Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : ASKB589
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Aosaikang Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ASKG712
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Aosaikang Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of ASKG712 in Patients With Diabetic Macular Edema
Details : ASKG712 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Macular Edema.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 11, 2023
Lead Product(s) : ASKG712
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Aosaikang Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ASKG915
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Aosaikang Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
Details : ASKG915 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 22, 2023
Lead Product(s) : ASKG915
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Aosaikang Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ASKB589
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Aosaikang Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ASKB589 is a drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Stomach Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 01, 2022
Lead Product(s) : ASKB589
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Aosaikang Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ASKG315
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Aosaikang Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of ASKG315 in Patients With Advanced Solid Tumors.
Details : ASKG315 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 26, 2022
Lead Product(s) : ASKG315
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Aosaikang Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ASKG315
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Aosaikang Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 Study of ASKG315 in Patients With Advanced Solid Tumors
Details : ASKG315 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 22, 2022
Lead Product(s) : ASKG315
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Aosaikang Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ASKG712
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Sponsor : Aosaikang Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration
Details : ASKG712 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Wet Macular Degeneration.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
July 13, 2022
Lead Product(s) : ASKG712
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Sponsor : Aosaikang Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ASKG712
Therapeutic Area : Ophthalmology
Study Phase : Phase I
Recipient : AffaMed Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In pre-clinical studies, AM712 (ASKG712) demonstrated robust efficacy, good ocular pharmacokinetics, and the desired safety profile supporting clinical exploration. AM712 is a novel bispecific biologic molecule specifically designed for ocular use.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 30, 2022
Lead Product(s) : ASKG712
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I
Recipient : AffaMed Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Recipient : GenScript ProBio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : The single-domain antibodies involved in this license agreement will be paired with AskGene's proprietary next-generation cytokine therapeutics for cancer immunotherapy and other applications.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 26, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Recipient : GenScript ProBio
Deal Size : Undisclosed
Deal Type : Licensing Agreement
